73,700 Shares in Boston Scientific Corporation $BSX Acquired by Encore Global Management LP

Encore Global Management LP acquired a new stake in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, HoldingsChannel.com reports. The fund acquired 73,700 shares of the medical equipment provider’s stock, valued at approximately $3,146,000. Boston Scientific accounts for about 3.1% of Encore Global Management LP’s portfolio, making the stock its 13th biggest position.

Other hedge funds have also recently added to or reduced their stakes in the company. B. Metzler seel. Sohn & Co. AG bought a new stake in shares of Boston Scientific during the second quarter worth $14,237,000. TrinityBridge Ltd bought a new position in shares of Boston Scientific in the 2nd quarter valued at $291,000. Portfolio Design Labs LLC acquired a new stake in shares of Boston Scientific during the 2nd quarter valued at $342,000. Advisors Capital Management LLC acquired a new stake in shares of Boston Scientific during the 2nd quarter valued at $336,000. Finally, PCM Encore LLC bought a new stake in Boston Scientific during the 2nd quarter worth $239,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In other news, Director Edward J. Ludwig purchased 5,000 shares of the company’s stock in a transaction dated Friday, July 31st. The shares were purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Michael F. Mahoney acquired 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders bought 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

BSX has been the subject of several research reports. Canaccord Genuity Group dropped their target price on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a research note on Friday, June 12th. Argus reiterated a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $60.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. Finally, Stifel Nicolaus set a $60.00 price target on shares of Boston Scientific in a research report on Wednesday, July 29th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Trading Up 2.1%

Shares of BSX stock opened at $50.39 on Friday. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The stock has a market cap of $73.03 billion, a price-to-earnings ratio of 20.40, a PEG ratio of 1.08 and a beta of 0.56. The stock has a 50-day moving average of $46.34 and a 200-day moving average of $57.86.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the previous year, the firm earned $0.75 earnings per share. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has approved a stock repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.